Close Menu

Personalis

Invitae said this week that it completed its acquisition of Singular Bio on June 19.

The company is offering around 7.9 million shares of common stock at a price of $17 per share and is granting the underwriters an option to buy an additional 1.2 million shares.

The company expects to offer 6.7 million common shares at a maximum offering price of $16 per share.

FLX Bio will apply Personalis' ImmunoID Next platform as part of a Phase I/II clinical trial evaluating its FLX475 drug in cancer therapy.

The ACE ImmunoID test uses exome and transcriptome sequencing to identify neoantigens for the development of personalized cancer vaccines.

The contract was awarded as part of the VA's Precision Oncology Program, which aims to provide advanced clinical care and generate cancer biomarker data.

The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.

The firm has received approval for two unspecified clinical tests, with a permit under the molecular genetic testing category.

Researchers compared three open source annotation tools, and also looked at correspondence with public databases, identifying a number of stumbling blocks.

The companies will use Personalis' ACE ImmunoID next-generation sequencing platform to analyze tumor samples from clinical trials of Argos' drug.

Pages

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.